Physician profile
Robert S Renouard
NPI 1265492144
$9,043.46
in general payments reported to CMS, 2019-2025
36 companies · $585 in 2025
The $585 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $964 · 2020: $303 · 2021: $597 · 2022: $3,884 · 2023: $1,837 · 2024: $872 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,180 · Travel and Lodging: $960 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,180.16 |
| Travel and Lodging | $960.40 |
| Education | $153.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $2,660.74 | 2021-2025 | Urolift, Barrigel |
| Palette Life Sciences, INC. | $1,329.37 | 2023 | |
| Urogen Pharma, INC. | $950.11 | 2021-2025 | Jelmyto |
| Profound Medical Corp. | $842.81 | 2022 | |
| Astellas Pharma US INC | $612.48 | 2019-2023 | Myrbetriq |
| Medtronic, INC. | $339.71 | 2021-2024 | Interstim |
| Healthtronics Stone Solutions, LLC | $268.10 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $261.01 | 2023-2025 | Gemtesa, Orgovyx |
| Coloplast Corp | $260.67 | 2019-2022 | |
| Boston Scientific Corporation | $209.30 | 2019-2022 | |
| Pfizer INC. | $164.07 | 2019-2025 | |
| Urovant Sciences INC | $144.41 | 2021-2022 | |
| Allergan, INC. | $136.70 | 2019 | |
| Accord Healthcare, INC. | $91.08 | 2023-2025 | |
| Blue Earth Diagnostics | $90.75 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $87.64 | 2019-2022 | |
| Myovant Sciences INC. | $58.93 | 2021 | |
| Abbvie INC. | $55.55 | 2019 | |
| Edap Technomed INC | $52.71 | 2022 | |
| Convatec INC. | $49.29 | 2022 | |
| Neotract INC. | $39.74 | 2020 | |
| Tolmar, INC. | $37.44 | 2024-2025 | Eligard, Jatenzo |
| Endo Pharmaceuticals INC. | $37.06 | 2019-2023 | Aveed, Xiaflex |
| Dendreon Pharmaceuticals LLC | $35.82 | 2022-2025 | Provenge |
| Amgen INC. | $26.94 | 2019-2020 | |
| Olympus America INC. | $24.60 | 2025 | Itind System |
| Travere Therapeutics, INC. | $22.07 | 2019 | |
| Axonics, INC. | $21.44 | 2022 | |
| Ferring Pharmaceuticals INC. | $20.29 | 2024 | Adstiladrin |
| Antares Pharma, INC. | $19.15 | 2021 | |
| Immunitybio, INC. | $18.00 | 2024 | |
| Alexion Pharmaceuticals, INC. | $17.11 | 2021 | |
| Innocoll Pharmaceuticals Limited | $16.17 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.04 | 2022 | |
| Therapeuticsmd, INC. | $14.66 | 2019 | |
| Civco Medical Instruments | $12.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Renouard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.